Danaher Corporation announced that Matthew Gugino, currently Group Chief Financial Officer of the Company’s Life Sciences Innovations Group and Vice President of Financial Planning & Analysis, will succeed Matthew McGrew as Danaher’s Chief Financial Officer effective February 28th, 2026. Following the transition and consistent with past practice, Mr. McGrew will continue thereafter as an Executive Vice President of the Company, as he begins a gradual transition to retirement, after more than 20 years with Danaher.
“Matt McGrew’s financial leadership over the past two decades has been instrumental in shaping the Danaher you see today. He played a pivotal role in the acquisition of Cytiva, the launches of Envista and Veralto as public companies, and navigating through the pandemic—all while developing a deep talent bench” said Rainer Blair, President and Chief Executive Officer. “We’re grateful he’ll remain with Danaher to support a seamless transition, and we look forward to building on his legacy.”
Also Read: Danaher Appoints Martin Stumpe as Chief Technology and AI Officer
Blair continued, “I’ve had the privilege of working closely with Matt Gugino for more than a decade. His broad experience across Investor Relations, FP&A, M&A, talent development, and most recently as Group CFO, makes him exceptionally well prepared for this next chapter. Matt has been instrumental in shaping our financial strategy and portfolio evolution, and I know he will be an outstanding CFO as we continue to grow Danaher into one of the world’s most respected science and technology leaders.”
Click here to join our WhatsApp channel here
Mr. McGrew has served as Danaher’s CFO since January 2019. He joined Danaher in 2004 as Director, M&A Finance and served in roles of increasing responsibility including Vice President, Investor Relations from 2009 to 2014 and as a Danaher Group CFO from 2012 to 2018. During his tenure as CFO, Danaher meaningfully increased its growth and margin profile, and nearly doubled both its revenue and market capitalization.
Mr. Gugino joined Danaher in 2013 as Director, Investor Relations and served as Vice President, Investor Relations from 2014 to 2022. He has served as Vice President of Financial Planning & Analysis since 2019 and additionally as Group Chief Financial Officer in the Company’s Life Sciences Innovations Group since 2021. Prior to joining Danaher, he was a Vice President of Equity Research at Barclays and Morgan Stanley, and an Associate at KPMG. He holds a Bachelor of Science degree in Accounting and a Master of Accountancy and Professional Consultancy from Villanova University.
